CAJ | 학술논문

目的:评价肿瘤标志物CA242与CA19-9在大肠癌诊断、治疗和预后中的临床意义.方法:应用酶联免疫吸附(ELISA)法检测35例大肠癌和204例非癌患者血清CA242与CA19-9的含量.结果:大肠癌患者血清CA242与CA19-9的含量(99.5±112.41U/mL和46.23±70.82U/mL)明显高于非癌患者(9.63±15.50U/mL和8.40±22.02U/mL)(P＜0.01).血清CA242对大肠癌诊断的敏感性、特异性和准确性分别为60%、96.57%和91.21%,血清CA19-9分别为31.43%、95.59%和86.19%.CA242与CA19-9比较,敏感性二者差异有显著性(P＜0.01),特异性和准确性差异无显著性(P＞0.05).联合检测CA242与CA19-9的敏感性为68.57%(24/35),明显高于单独检测CA19-9的敏感性(31.43%)(P＜0.01),略高于单独检测CA242的敏感性(P＞0.05).CA242与CA19-9对结肠癌诊断的敏感性为64.71%和41.18%,高于对直肠癌诊断的敏感性55.55%和22.22%(P＞0.05).大肠癌中血清CA242正常的患者治疗有效率为57.14%,CA242升高的有效率为14.29%(P＜0.01).CA19-9正常的患者治疗有效率为33.33%,CA19-9升高的有效率为27.27%(P＞0.05).随访3～14个月,CA242和CA19-9升高与正常的大肠癌患者的生存期均为2～14个月.中位生存期:CA242正常患者为9个月,CA242升高患者为6.5个月;CA19-9正常患者为7.5个月,升高患者为6.5个月.结论:血清CA242和CA19-9对大肠癌的诊断有一定的临床价值,且CA242的诊断作用优于CA19-9,二者联合检测可提高诊断的敏感性.二者检测有助于临床治疗疗效的评价、预后评估和病情随访监测.
목적:평개종류표지물CA242여CA19-9재대장암진단、치료화예후중적림상의의.방법:응용매련면역흡부(ELISA)법검측35례대장암화204례비암환자혈청CA242여CA19-9적함량.결과:대장암환자혈청CA242여CA19-9적함량(99.5±112.41U/mL화46.23±70.82U/mL)명현고우비암환자(9.63±15.50U/mL화8.40±22.02U/mL)(P＜0.01).혈청CA242대대장암진단적민감성、특이성화준학성분별위60%、96.57%화91.21%,혈청CA19-9분별위31.43%、95.59%화86.19%.CA242여CA19-9비교,민감성이자차이유현저성(P＜0.01),특이성화준학성차이무현저성(P＞0.05).연합검측CA242여CA19-9적민감성위68.57%(24/35),명현고우단독검측CA19-9적민감성(31.43%)(P＜0.01),략고우단독검측CA242적민감성(P＞0.05).CA242여CA19-9대결장암진단적민감성위64.71%화41.18%,고우대직장암진단적민감성55.55%화22.22%(P＞0.05).대장암중혈청CA242정상적환자치료유효솔위57.14%,CA242승고적유효솔위14.29%(P＜0.01).CA19-9정상적환자치료유효솔위33.33%,CA19-9승고적유효솔위27.27%(P＞0.05).수방3～14개월,CA242화CA19-9승고여정상적대장암환자적생존기균위2～14개월.중위생존기:CA242정상환자위9개월,CA242승고환자위6.5개월;CA19-9정상환자위7.5개월,승고환자위6.5개월.결론:혈청CA242화CA19-9대대장암적진단유일정적림상개치,차CA242적진단작용우우CA19-9,이자연합검측가제고진단적민감성.이자검측유조우림상치료료효적평개、예후평고화병정수방감측.